Pharmaceutical Executive January 21, 2026
Key Takeaways
- AI’s impact in pharma hinges on data, infrastructure, culture, and regulatory alignment, not just algorithms.
- AI can accelerate drug discovery, clinical development, and patient access, but regulatory hurdles remain.
- Companies should focus on specific AI use cases and build robust data and infrastructure for maximum impact.
- AI adoption in pharma is uneven; strategic focus and regulatory approval are crucial for broader implementation.
Anders Romare, Advisory Board Member, causaLens, and former Novo Nordisk CDIO, outlines why artificial intelligence represents a structural turning point for the pharmaceutical industry.
Drawing on decades at the center of global pharmaceutical strategy and innovation, former Novo Nordisk Chief Digital Information Officer and current Advisory Board Member at causaLens Anders Romare discusses a...
Today's Sponsors
Today's Sponsor